Takashi Owa

6.1k citations
53 papers · 4.6k · 3 hit papers · h-index 25

Impact in

    • Synthesis and Catalytic Reactions
    • Synthesis and biological activity
    • Enzyme function and inhibition
    • Histone Deacetylase Inhibitors Research
    • Protein Degradation and Inhibitors
    • RNA Research and Splicing
    • RNA modifications and cancer
    • Epigenetics and DNA Methylation

Papers in

    • Enzyme function and inhibition 13
    • Cancer therapeutics and mechanisms 6
    • Ubiquitin and proteasome pathways 6
    • Protein Degradation and Inhibitors 5
    • Chemical Synthesis and Analysis 5
    • Histone Deacetylase Inhibitors Research 5

Takashi Owa

51 papers receiving 4.5k citations

Takashi Owa's Hit Papers

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study 2018 · 451 citations
4510+7+15Years since publication200400600

Peers

Takashi Owa
Comparison fields: 5 of 125
  • Organic Chemistry 1.7k
  • Molecular Biology 3.0k
  • Cancer Research 473
  • Oncology 716
  • Toxicology 82
Replace Kevin T. Chapman with:
Kevin T. Chapman United States
Jeremy I. Levin United States
Wenfang Xu China
William K. Hagmann United States
Roger J. Griffin United Kingdom
Nicholas J. Lawrence United States
Arie Zask United States
Raphaël Rodriguez France
Allan M. Jordan United Kingdom
Shijun Wen China
Takashi Owa relative to Kevin T. Chapman United States Kevin T. Chapman's profile →
Citations per field
00.5×3.6×
Kevin T. Chapman · 1×
Citations per year

Countries citing papers authored by Takashi Owa

Since Specialization
Citations

This map shows the geographic impact of Takashi Owa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takashi Owa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takashi Owa more than expected).

Fields of papers citing papers by Takashi Owa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takashi Owa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takashi Owa. The network helps show where Takashi Owa may publish in the future.

Co-authors

The 25 scholars most cited alongside Takashi Owa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Takashi Owa Line = papers co-authored together Takashi Owa links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 53 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Anticancer and Antiviral Sulfonamides
Hit paper breakdown →
2003642
2
Splicing factor SF3b as a target of the antitumor natural product pladienolide
Hit paper breakdown →
2007500
3
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Hit paper breakdown →
2018451
4 1998320
5 2017279
6 1999265
7 2003224
8 1998162
9 2003154
10 1999144
11 2001142
12 2000140
13 2000128
14 2004124
15 2001111
16
Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium.
200294
17 201882
18 200181
19 200676
20 200266

About Takashi Owa

Takashi Owa is a scholar working on Molecular Biology, Organic Chemistry, Oncology, Pharmacology and Cancer Research, having authored 53 papers that have together received 4.6k indexed citations. Recurring topics across this work include Enzyme function and inhibition (13 papers), Cancer therapeutics and mechanisms (6 papers), Ubiquitin and proteasome pathways (6 papers), Protein Degradation and Inhibitors (5 papers), Chemical Synthesis and Analysis (5 papers), Histone Deacetylase Inhibitors Research (5 papers), Synthesis and Biological Activity (4 papers) and Microbial Natural Products and Biosynthesis (4 papers). The work is most often cited by research in Organic Chemistry (1.7k citations), Molecular Biology (3.0k citations), Cancer Research (473 citations), Oncology (716 citations) and Toxicology (82 citations). Takashi Owa has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Andrea Scozzafava, Claudiu T. Supuran, Takeshi Nagasu, Antonio Mastrolorenzo, Stuart L. Schreiber, Kentaro Yoshimatsu, Christian A. Hassig, Naoko Hata Sugi, Mai Uesugi and Koji Sagane. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of Medicinal Chemistry, Proceedings of the National Academy of Sciences, Current Medicinal Chemistry and Chemistry Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact